Tissue factor targeting peptide enhances nanoparticle binding and delivery of a synthetic specialized pro-resolving lipid mediator to injured arteries.

We observed a trend toward reduced myeloperoxidase staining in arteries treated with benzo-RvD1, but this did not achieve significance (vehicle 33.2 vs targeted blank 80.8 vs scrambled benzo 25.2 vs targeted benzo 13.4 positive nuclei/mm 2 , ANOVA; P = .055) ( Supplementary Fig, A ).

also in 1,397 other papers

Arteries treated with targeted benzo-RvD1 NP demonstrated a nonsignificant trend toward lower CD45 + counts, as did those treated using scrambled NPs loaded with benzo-RvD1 (0.76 ± 0.76 and 8.9 ± 2.41 vs vehicle 59.31 ± 32.02 and targeted control 122.1 ± 62.9; P = ns).

also in 5,406 other papers